Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)

Trial Profile

Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2018

At a glance

  • Drugs Canerpaturev (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms Neo-NivoHF10
  • Most Recent Events

    • 21 Dec 2017 According to a Takara Bio media release, has entered into an agreement with Huntsman Cancer Institute (HCI) to supply HF10 as an investigational drug. Under the agreement HCI will conduct this trial.
    • 13 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 13 Nov 2017 Planned initiation date changed from 1 Oct 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top